DocGo vs Fulgent Genetics
Fulgent Genetics reported revenue of $323 million in fiscal 2025, about the same as DocGo's $322 million in fiscal 2025. DocGo's revenue fell 47.7% in its latest year, and Fulgent Genetics' grew 13.8%. DocGo had an operating margin of -55.3%, against -28.2% at Fulgent Genetics. Free cash flow was $30 million at DocGo and −$124 million at Fulgent Genetics.
Side by side
| DocGo | Fulgent Genetics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $322M | $323M |
| Revenue growth | −47.7% | 13.8% |
| Revenue growth a year, last 5 years | 27.9% | −5.2% |
| Gross margin | — | 40.6% |
| Operating margin | −55.3% | −28.2% |
| Net margin | −56.6% | −18.8% |
| Free cash flow | $30M | −$124M |
| Free cash flow margin | 9.3% | −38.5% |
| Return on capital | −84.6% | −8.7% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $11M | $11M |
| Change in diluted share count | −9.5% | 1.8% |
| Last close | $0.17 | $24.78 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $15,334 | sold $386,628 |
| Piotroski F-score | 3 of 8 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
DocGoFulgent Genetics
Operating margin
Percent of revenue
DocGoFulgent Genetics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
DocGoFulgent Genetics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the DocGo and Fulgent Genetics pages.